Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks
Source: SeekingAlpha
2025-08-06 21:48:01 ET
More on Seres Therapeutics
- Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
- Seres?Therapeutics: Speculative Gem Backed By SER?155 FDA Breakthrough
- Seres Therapeutics GAAP EPS of -$2.27 beats by $0.22
- Seeking Alpha’s Quant Rating on Seres Therapeutics
- Historical earnings data for Seres Therapeutics
Read the full article on Seeking Alpha
For further details see:
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks
Seres Therapeutics Inc.
NASDAQ: MCRB
MCRB Trading
-0.46% G/L:
$8.69 Last:
19,989 Volume:
$9 Open:
MCRB Latest News
March 12, 2026 07:00:00 am
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
MCRB Stock Data
$129,727,082
7,418,146
0.38%
16
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
